0001493152-23-033815.txt : 20230927 0001493152-23-033815.hdr.sgml : 20230927 20230927060559 ACCESSION NUMBER: 0001493152-23-033815 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230926 FILED AS OF DATE: 20230927 DATE AS OF CHANGE: 20230927 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: van der Baan Bastiaan Jeroen CENTRAL INDEX KEY: 0001938070 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39717 FILM NUMBER: 231281745 MAIL ADDRESS: STREET 1: HOGEWEG 4-H CITY: AMSTERDAM STATE: P7 ZIP: 1098CB ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LIXTE BIOTECHNOLOGY HOLDINGS, INC. CENTRAL INDEX KEY: 0001335105 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202903526 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 248 ROUTE 25A STREET 2: NO. 2 CITY: EAST SETAUKET STATE: NY ZIP: 11733 BUSINESS PHONE: 310 203 2902 MAIL ADDRESS: STREET 1: 248 ROUTE 25A STREET 2: NO. 2 CITY: EAST SETAUKET STATE: NY ZIP: 11733 FORMER COMPANY: FORMER CONFORMED NAME: SRKP 7 INC DATE OF NAME CHANGE: 20050803 4 1 ownership.xml X0508 4 2023-09-26 0 0001335105 LIXTE BIOTECHNOLOGY HOLDINGS, INC. LIXT 0001938070 van der Baan Bastiaan Jeroen HOGEWEG 4-H AMSTERDAM P7 P71098CB NETHERLANDS 1 1 0 0 President and CEO 0 Options to Purchase Common Stock 1.95 2023-09-26 4 A 0 250000 0 A 2028-09-26 Common 250000 250000 D Options to Purchase Common Stock 5.88 2023-06-30 4 A 0 10000 0 A 2023-06-30 2028-06-30 Common 10000 10000 D Options to Purchase Common Stock 7.40 2022-06-17 4 A 0 25000 0 A 2022-06-17 2027-06-17 Common 25000 25000 D In connection with the Employment Agreement dated as of September 26, 2023 between the Company and the reporting person, the reporting person was granted stock options to purchase an aggregate of 250,000 shares of common stock, vesting quarterly over a three-year period commencing on the last day of each calendar quarter commencing October 1, 2023 until fully vested. NOTE: Effective June 2, 2023, the Issuer effected a 1-for-10 reverse split of its outstanding shares of common stock. Accordingly, the exercise price and the amount of underlying shares of common stock set forth above for all transactions entered into prior to that date have been adjusted to reflect the reverse stock split. /s/ Bastiaan van der Baan 2023-09-27